BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

...cancer and NSCLC. BeyondSpring Inc. (NASDAQ:BYSI) Clinical Results , Product Profile Cardiovascular; hematology Cardiovascular; hemophilia Bone marrow stromal cell antigen 1...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cardiovascular; hematology

...testing the BST1/CD200-positive vascular endothelial cells in additional models of vascular injury and hemophilia. TARGET/MARKER/PATHWAY: Bone marrow stromal cell antigen 1...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Cytomegalovirus (CMV) Bone marrow stromal cell antigen 2 (BST2; CD317) In vitro studies suggest inhibiting BST2 could help treat CMV...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Hepatic disease IL-15; bone marrow stromal cell antigen 2 (BST2; CD317) Mouse and patient sample studies suggest blocking IL-15 or depleting dendritic cells could...
BioCentury | Dec 3, 2009
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Proteomics-based identification of potential lymphoma drug targets A proteomics assay could be useful for identifying new targets to treat lymphoma. In lymphoma-bearing mice, infusion...
Items per page:
1 - 5 of 5